Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES-NK Cell Injection in Refractory Lupus Nephritis
NCT07412210Phase 1Not yet recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Apr 2026
- Primary completion
- Mar 2029
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells, Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of AXA-NK02 in lupus nephritis (LN) and systemic lupus erythematosus (SLE), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Incidence and severity of Adverse Events at 2 years. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
AXA-NK02
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07412210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412210.